Companies /Healthcare

Johnson & Johnson

NYSE: JNJ Drug Manufacturers - General

$266.73

▼ $5.22 (−1.92%) today

Markets open · 12:58pm ET

24/7 Wall St. View

Price Prediction $311.09 +14.4% Our analysts’ 12-month view: target, optimistic case, and floor. Full prediction → Earnings EPS vs. the estimate, revenue, and how the market reacted. Total Earnings Coverage →

Fundamentals

Market Cap

$655.4B

P/E Ratio

31.4

Dividend Yield

1.93%

Profit Margin

21.5%

Revenue (TTM)

$97.9B

EPS (TTM)

$8.65

52-Week Range

$179 – $281

Street Target

$277.91

About Johnson & Johnson

Johnson & Johnson is a global healthcare giant founded in 1886, headquartered in New Brunswick, New Jersey. It operates in the healthcare sector, offering a wide range of products across various therapeutic areas including immunology, infectious diseases, neuroscience, oncology, cardiovascular, and metabolism. Additionally, it has a MedTech segment that provides interventional solutions, orthopaedics, surgery technologies, contact lenses, and intraocular lenses. The company's products are distributed worldwide to retailers, wholesalers, hospitals, and healthcare professionals, emphasizing its commitment to improving health for people everywhere.

Latest Activity

House trade disclosureThomas H. Kean, Jr.

Sep 12

GOOGLAlphabet Inc. - Class A Common Stock (GOOGL)Partial sell$1K – $15KAug 27
AMCRState Street Bank & Trust Co. Amcor plc Ordinary Shares (AMCR)Partial sell$1K – $15KAug 10
JNJKean Family Partnership Johnson & Johnson Common Stock (JNJ)Partial sell$1K – $15KAug 27
LINState Street Bank & Trust Co. Linde plc - Ordinary Shares (LIN)Buy$1K – $15KAug 10
MTZKean Family Partnership MasTec, Inc. Common Stock (MTZ)Buy$1K – $15KAug 21
MSFTKean Family Partnership Microsoft Corporation - Common Stock (MSFT)Partial sell$15K – $50KAug 27

Made public 33 days after the earliest trade

Kean trimmed megacap tech on the same August day, with the Microsoft sale the largest line in the filing, and rotated the proceeds toward industrial gas and infrastructure names. Disclosed 33 days after the trades, so the rotation out of Big Tech and into picks-and-shovels was already done before anyone could see it.

JNJ Coverage

9:03am ET

Investing

Why Amgen’s 6% Dividend Raise Masks a Tougher Road Ahead

Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.

AMGN JNJ PFE

Chris Lange

8:00am ET

Investing

Living Off Dividends at 65: 3 Stocks That Raised Payouts for Longer Than 30 Years

Three stocks have raised their dividends for over 30 consecutive years through recessions, wars, and market crashes, and one has paid shareholders without interruption for 136 years straight. Find out which name…

JNJ KO PG

Joel South

2:41pm ET

Personal Finance

How Large Does Your Portfolio Need to Be to Generate $8,350 a Month?

The portfolio size needed to generate a six-figure passive income swings by nearly $2 million depending on one decision, and getting that decision wrong could leave your monthly check vulnerable to a…

FDVV GBDC JAAA

David Beren

2:00pm ET

Investing

Johnson & Johnson’s Next Growth Engine Is Taking Shape

Johnson & Johnson's oncology and immunology pipeline is firing on multiple cylinders, but a collapsing blockbuster drug and mounting litigation costs threaten to cancel out every gain. Here is whether the bull…

ABBV JNJ MRK

Vandita Jadeja

9:30am ET

Investing

Want Bulletproof Dividend Income? These 3 Stocks Have Raised Payouts Through 8 Major Downturns

Three companies have written dividend checks through stagflation, financial collapse, and a global pandemic without missing a single annual raise, but the headwinds each faces right now will test whether history really…

JNJ KO PG

Joel South

11:01am ET

Investing

ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade

AbbVie and Johnson and Johnson both trade near 52-week highs and carry decades of dividend raises, but one faces a patent cliff and a leveraged balance sheet that could force retirees to…

ABBV JNJ

Chris Lange

10:00am ET

Investing

The 1 Number That Decides Whether a Dividend Lasts Your Whole Retirement

Most retirees obsess over yield and payout ratios, but neither metric has actually survived a recession, a rate spike, or a global pandemic on your behalf. One number has, and it changes…

JNJ

Joel South

1:58pm ET

Investing

Dave Ramsey Says You Need More Than 6% Just to Break Even. Dividend Growth Is One Way to Get There.

A bond coupon that felt safe a decade ago may be quietly bleeding your retirement dry, and Dave Ramsey's hurdle-rate math explains exactly why. The question is which assets can actually climb…

ADP JNJ KO

Chris Lange

1:31pm ET

Investing

CDs Offer Certainty. Dividend Stocks Offer Something Retirees May Need More

When a retiree compares a federally insured CD to a dividend stock that has raised its payout for 70 straight years, the choice turns on a factor most income calculators ignore entirely.

JNJ PG

Chris Lange

9:01am ET

Investing

4 Elite Dividend Stocks Yielding Up to 6.14% With Diversified Pipelines That Protect Your Payout

Patent cliffs have buried lesser pharma dividends, yet these four Big Pharma giants keep raising payouts despite losing blockbuster exclusivities worth billions. Find out which one has held its streak for 64…

BMY JNJ MRK

Chris Lange

6:01am ET

Investing

3 Dividend Stocks Built for Retirement to Buy in September

Retirement portfolios need income that shows up on time, grows faster than inflation, and does not blink during a downturn. The three names below cover three distinct roles: a healthcare Dividend King…

JNJ JPM O

Joel South

8:45am ET

Investing

The Moneymaxxing Crowd Will Love 5 High-Yield Dividend Stocks Under $20

Younger investors are rewriting the rules of wealth building, and five overlooked dividend stocks under $20 sit right at the center of that shift. The real question is whether these picks can…

AES F GWRS

Lee Jackson

4:00pm ET

ETF

Even With $262,000 in VYM, You Wouldn’t Get a $500 Check Every Month

Retirees chasing a simple $500 monthly check from VYM run straight into a gap between how yields are calculated and how cash actually lands in your account, and the math gets uncomfortable…

AVGO CAT JNJ

Omor Ibne Ehsan

11:36am ET

Investing

Monthly Paydays vs. Compound Growth: Why JNJ Beats O for Long-Term Retirees

Realty Income pays you every month while Johnson and Johnson barely clears 2% yield, yet one of these retirement staples is quietly demolishing the other where it counts most for a 20-year…

JNJ O

Chris Lange

6:01am ET

Investing

3 Dividend Stocks Baby Boomers Should Own for the Rest of Their Lives

Some dividend stocks hand retirees a check and a prayer. These three have raised their payouts through every recession for over half a century, and the reason one of them keeps getting…

JNJ KO PEP

Joel South